Nedosiran

Nedosiran, sold under the brand name Rivfloza, is a medication used for the treatment of primary hyperoxaluria.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Nedosiran, sold under the brand name Rivfloza, is a medication used for the treatment of primary hyperoxaluria. It is an LDHA-directed small interfering RNA developed by Dicerna Pharmaceuticals. The most common side effects include injection site reactions.

Nedosiran was approved for medical use in the United States in September 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1292966513 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

6 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.